Bristol-Myers Squibb (BMY)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.06% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- 2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One)
- Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
- 5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong
- AeraHUB 26 NYC Brings the Decision-Centric Enterprise to Life
- Bristol Myers Squibb (BMY) Secured A Camzyos Label Expansion, Is It Still Undervalued?
- Sotyktu Gains Ground in Psoriatic Arthritis, but Rheumatologists Remain Selective as Its Role in the Treatment Algorithm Takes Shape, According to Spherix Global Insights
- Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA
- Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here’s Why it Matters
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Bristol-Myers Squibb.
Full BMY Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.